Claim OwnershipThe BioHub: The Top Voices in Biotech
Subscribed: 11Played: 18
Subscribe
© Max Brennan - Biotech HeadHunter
Description
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape.
Subscribe now and be part of the conversation that's shaping the future of biotechnology.
Get ready for an immersive experience into the world of biotech with The BioHub.
Subscribe now and be part of the conversation that's shaping the future of biotechnology.
Get ready for an immersive experience into the world of biotech with The BioHub.
168 Episodes
Reverse
In this episode of The BioHub Podcast, Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals.Cary’s career spans finance, M&A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder.In this conversation, Cary shares his transition into biotech leadership, what it’s like running a micro-cap clinical-stage company, and how Adial is approaching one of the most complex and underserved areas in medicine.They also discuss leadership, resilience, and the realities of building and financing biotech companies in today’s market.
Welcome to another episode of The BioHub.Today I’m joined by Steffen-Sebastian Bolz — scientist, physician, entrepreneur, and Co-Founder of Aphaia Pharma, a clinical-stage biotech developing precision-targeted drug formulations to treat and prevent metabolic disorders like obesity and prediabetes.We’ll be talking about the science behind Aphaia, why they’re not building with an exit in mind, and how staying lean and under the radar has helped them advance to Phase 2.
In this episode of The BioHub Podcast, Max sits down with Dr. Philippe Chambon, CEO and Co-Founder of EG 427.After more than 30 years in pharma and venture capital — raising over $1 billion to back life science companies — Philippe has made the move from investor to operator, now leading EG 427.The company is pioneering a new approach to neurological disease with pinpoint DNA medicine, designed for precise and durable delivery.In this conversation, Philippe shares his journey into the CEO seat, the inspiration behind EG 427, and why he believes Europe — and France in particular — are entering a new era for biotech innovation.
Today’s guest is Dr. Yerem Yeghiazarians — a leading interventional cardiologist, professor of medicine at the University of California, San Francisco, and a physician-scientist working at the cutting edge of cardiovascular innovation.With medical training from Johns Hopkins and advanced cardiology specialization at Brigham and Women’s Hospital, Dr. Yeghiazarians has spent over two decades at UCSF treating complex heart disease and advancing the field of interventional cardiology.Dr. Yeghiazarians is the co-founder of Soley Therapeutics, a biotech company focused on using AI to better understand how cells respond to stress, injury, and disease — with the goal of transforming how new drugs are discovered and developed.Alongside this, he directs translational research exploring how stem cell therapies can repair heart damage after heart attacks, bridging fundamental science with real-world clinical impact.From the cath lab to the biotech startup world, his career sits at the intersection of medicine, technology, and entrepreneurship — and today, we’ll explore that journey, the future of drug discovery, and what it takes to turn scientific insight into meaningful breakthroughs.
In this episode of The BioHub Podcast, Max sits down with Amit Etkin, Founder and CEO of Alto Neuroscience.Psychiatry is one of the few areas in medicine still dominated by trial and error.Amit is trying to change that.A trained psychiatrist and neuroscientist, Amit founded Alto to bring precision medicine into mental health — using biomarkers to better match patients with the treatments that actually work for them.In this conversation, we get into why CNS drug development has historically struggled, what’s broken in the current system, and how a more data-driven approach could reshape the future of psychiatry.We also talk about Amit’s journey from academia to founder, the realities of building in a tough market, and why now might finally be the turning point for neuroscience.A thoughtful, honest conversation tackling one of the hardest problems in medicine. 🧠
We were delighted to be joined by James Kim (Chief Corporate Officer) and Ronald Li (Chief Executive Officer), at Medera Biopharmaceuticals.Medera is a company at the forefront of pharmaceutical innovation, focused on advancing next-generation therapies and building a globally competitive platform across research, development, and commercialization. As the industry continues to evolve — driven by scientific breakthroughs, regulatory complexity, and shifting market dynamics — Medera is positioning itself to play a meaningful role in shaping what comes next.James and Ronald sit right at the center of that journey. Between them, they bring deep experience across strategy, operations, and scaling healthcare businesses, with a strong focus on translating innovation into real-world impact.
Today, we’re joined by Dipal Doshi, a leader at theforefront of modern biotechnology and rare disease innovation. As CEO of Entrada Therapeutics, Dipal has helped build the company from its earliest days into a clinical-stage pioneer focused on unlocking intracellular therapies.With a career that spans investment banking at MerrillLynch, global pharma at Eli Lilly and Company, and senior leadership roles at Amicus Therapeutics, Dipal brings a unique blend of financial, strategic, and commercial expertise to the biotech world.Now Dipal's leading Entrada Therapeutics, who are aclinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, they are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.
In this episode of The BioHub Podcast, Max sits down with Barry Quart, CEO of Connect Biopharma and one of the most experienced biotech leaders in the industry.Barry’s career spans more than three decades across biotech and pharma, including founding Ardea Biosciences (acquired by AstraZeneca) and leading Heron Therapeutics, where he helped bring multiple drugs through development and approval. Across his career he has played a role in nine FDA-approved medicines.In this conversation, Barry shares the lessons he’s learned building biotech companies, what it really takes to develop successful drugs, and how he thinks about leadership in an industry defined by risk and long timelines.They also dive into Connect Biopharma, the company’s strategy in inflammatory diseases, and the potential of their lead program targeting the IL-4 pathway in asthma and other respiratory conditions.It’s a conversation about building companies, developing medicines, and navigating the realities of biotech.
In this episode of The BioHub, I’m joined by Catherine Isted, Chief Financial Officer of Santhera Pharmaceuticals.Catherine’s career journey is a unique one, from starting as a bench scientist, to nearly two decades in healthcare investment banking, and now leading finance at multiple biotech companies.In this International Women’s Day special, we talk about her path through the industry, the importance of diversity of thought in biotech, her experiences building a career in leadership, and her advice for young women looking to enter the field.
Today I’m joined by Rich Daly, CEO of Catalyst Pharmaceuticals — one of the standout rare-disease success stories in the industry and recently named one of America’s most successful small-cap companies by Forbes.Rich has spent more than 25 years leading organisations across biotech and pharma — including AstraZeneca, BeyondSpring, CARsgen, and others — and now he’s steering Catalyst as they expand their portfolio, grow their footprint, and continue delivering life-changing treatments for patients with rare neuromuscular and neurological diseases.We talk about what drew him to Catalyst, how the company thinks about growth, patient service, and rare-disease strategy, how they find the right drugs in a competitive market, and how Catalyst continues to outperform despite the volatility across biotech.Let’s get into it.
We were delighted to welcome Jason Ehrlich, Co-Founder and CEO of Ollin Biosciences onto the BioHub. Ollin are a clinical-stage biotechnology company focused on advancing next-generation therapies form serious eye diseases, including wet age-related macular degeneration anddiabetic macular edema. Before launching Ollin, Jason served as Chief MedicalOfficer and Chief Development Officer at Kodiak Sciences, where he led clinical development in retinal disease. Earlier in his career, he held senior leadership roles at Genentech, one of the pioneers in biologic medicines, helping advance therapies that have transformed care for patients with vision-threatening conditions.Trained as both a physician and a scientist, Jason brings arare blend of clinical insight, translational research expertise, and strategic leadership. His career sits at the intersection of medicine, innovation, and company building — with a clear focus: delivering meaningful, durable therapies to patients who risk losing their sight.
In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical.Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes.We discuss the science behind the platform, why long-acting implants could shift the treatment paradigm, what’s happening at Vivani right now, and what it takes to build and finance a biotech company in today’s market.
Today’s guest is Terry J. Rosen, a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy.Dr. Rosen is the co-founder and CEO of Arcus Biosciences, a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015—an early validation of his vision in immune-based therapies.Across his career, Terry has held senior scientific and leadership roles at major biopharmaceutical organizations including Amgen, Pfizer, and Abbott Laboratories, building a track record that bridges rigorous medicinal chemistry with bold company creation.In this we discuss:Arcus' pipeline and what makes them stand out from other companies in the immuno-oncology fieldWhat makes Arcus a compelling investment opportunity today and how they balance the long timelines and risks of drug development with the expectations of public markets and investors?The key milestones for Arcus in the next year to18 months that the scientific and investment communities should be paying attention to
In this episode of The BioHub, I’m joined by Thijs Spoor, CEO of Perspective Therapeutics.Thijs has taken an unconventional path to the CEO seat, bringing decades of leadership experience across healthcare and capital markets into one of the most exciting areas of biotech: targeted radiopharmaceuticals.We talk about his journey into the industry, the science and vision behind Perspective, the company’s recent $175M raise, and the milestones that could define their next phase of growth. A great conversation about bold strategy, differentiated science, and building momentum in today’s market.
We were delighted to welcome Declan Doogan, CEO of Causeway Therapeutics, onto The BioHub! Declan is a highly respected leader in the biopharmaceutical industry, with decades of experience spanning drug development, clinical research, and executive leadership at some of the world’s leading pharmaceutical companies.Throughout his career, he has played a pivotal role in advancing innovative therapies from early discovery through to global commercialization. At Causeway Therapeutics, he is leading the charge in developing breakthrough treatments aimed at addressing serious and underserved medical needs.In this we discuss:Entrepreneurship and building a biotech having spent decades in PharmaCauseway's recent encouraging clinic results and what makes there approach different to what's out there alreadyHow Causeway are thinking about the pipeline and upcoming milestones
In this episode of The BioHub, I’m joined by Raj Devraj, CEO of Rectify Pharma and Venture Partner at Atlas Venture.Raj has spent his career building biotech companies around bold science, including co-founding Disarm Therapeutics, which was acquired by Eli Lilly. Now he’s doing it again with Rectify.We talk about starting companies from zero, building the right teams early, de-risking new ventures, and the realities of fundraising in today’s biotech market. A practical, honest conversation with a true biotech builder.
We were delighted to welcome Simeon George, the CEO and Managing Partner of SR One Capital Management, a global biotech venture capital firm he helped spin out of GSK, onto the BioHub! He’s a physician by training, with an MD from the University of Pennsylvania, an MBA from Wharton, and a background that also includes time at Bain & Company and Goldman Sachs.Over the years, Simeon has helped build and back some of the most impactful companies in modern biotech, including CRISPR Therapeutics, Turning Point Therapeutics, and Principia Biopharma, among many others. He’s also a co-founder and board member of multiple biotech companies, working closely with scientists and founders to bring new medicines to patients
Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent.Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the course of her career, she’s built and scaled people strategies across both life sciences and financial services, holding senior HR leadership roles at organizations like the Broad Institute of MIT and Harvard, Warp Drive Bio, Aegerion Pharmaceuticals, and several major financial institutions.In this we discuss:Kim's 8.5 year journey so far at Fulcrum, from a small, ambitious biotech to the more mature, resilient organization it is today.Restructuring and the lessons learnt about leadership,communication, and empathy during times of crisisKim's new book 'The Culture Shock'
In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics.Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies.We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and why their precision gene therapy approach is so exciting. It’s a thoughtful conversation about mindset, leadership, and what it really takes to build in small biotech.
We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio.Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.In this we cover: The spark that led to the founding of Enara BioEnara's platform EDAPT® and how it finds dark antigens in tumors.Where the field of T-Cell therapy for solid tumors is today.The importance of culture in early stage biotech, and how the company has been built around putting people first.The next major milestones for Enara Bio.
Comments
Download from Google Play
Download from App Store
United States